Back to search results

Enfortumab Vedotin Plus Pembrolizumab With Selective Bladder Sparing for Treatment of Muscle-invasive Bladder Cancer

Abroad (travel likely)RecruitingPHASE2

Conditions

Muscle Invasive Bladder Urothelial Carcinoma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • City of Hope, Duarte, California, United States

    Contact: Study coordinator (Dorreth King-Rucker, MBA) · dkingrucker@coh.org · 626-218-9815
    Contact: Principal Investigator (Abhishek Tripathi, MD)

  • Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, Indiana, United States

    Contact: Study coordinator (Jessica Corman, CCRP) · jnorflee@iu.edu · 317-278-5646
    Contact: Principal Investigator (Tareq Salous, MD)

  • Icahn School of Medicine at Mount Sinai, New York, New York, United States

    Contact: Study coordinator (Lindsay Diamond) · lindsay.diamond@mssm.edu · 347-514-1561
    Contact: Principal Investigator (Matthew Galsky, MD)

  • Columbia University Irving Medical Center, New York, New York, United States

    Contact: Study coordinator (Denisse Mirauti) · dt2684@cumc.columbia.edu · 212-304-5485
    Contact: Principal Investigator (Alexander Wei, MD)

  • Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

    Contact: Study coordinator (Alexa Gerchman) · alexa.gerchman@fccc.edu
    Contact: Principal Investigator (Elizabeth Plimack, MD)
Study leads

  • Matthew Galsky, MD

    Principal Investigator

    Sponsor-Investigator

View source on ClinicalTrials.gov(opens in a new tab)